Lv21
200 积分 2022-08-02 加入
中国心血管健康与疾病报告2025概要
1个月前
已完结
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
2个月前
已完结
The Impact of Semaglutide on Weight Loss and Inflammation in People with HIV. An Observational Prospective Study in Greek Population
3个月前
已完结
Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial
4个月前
已完结
Peptide GLP-1 receptor agonists: From injection to oral delivery strategies
7个月前
已完结
Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review
8个月前
已完结
Cardiovascular Risk Models Using Large-Scale Physical Examination Data
9个月前
已关闭
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
11个月前
已完结
Two-year outcomes post-discharge in Asian patients with acute coronary syndrome: Findings from the EPICOR Asia study
1年前
已完结
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
1年前
已关闭
皖公网安备34019202002308
